Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00027859 · ClinicalTrials.gov registry record · Phase 3
Hormone Therapy Compared With Combination Chemotherapy in Treating Patients With Prostate Cancer
A Phase 3 study of Prostate Cancer, sponsored by Eastern Cooperative Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 20
- Study locations
NCT00027859: Completed Phase 3 study of Prostate Cancer, sponsored by Eastern Cooperative Oncology Group.
NCT00027859 is a Phase 3 study of Prostate Cancer that has completed, run by Eastern Cooperative Oncology Group. The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00027859, a Phase 3 study of Prostate Cancer, has completed, sponsored by Eastern Cooperative Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 20
- Study locations
Study Summary
RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Drugs such as ketoconazole may stop the production of androgens. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether hormone therapy is more effective than combination chemotherapy in treating prostate cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of hormone therapy with that of combination chemotherapy in treating patients who have prostate cancer that has been previously treated with androgen suppression.
Conditions Studied
Interventions
- DRUG docetaxel
- DRUG ketoconazole
- DRUG therapeutic hydrocortisone
- DRUG estramustine phosphate sodium
Study Locations (20)
Colorado
- Medical Center of Aurora - South Campus - Aurora
- Boulder Community Hospital - Boulder
- Penrose Cancer Center at Penrose Hospital - Colorado Springs
- Porter Adventist Hospital - Denver
- St. Joseph Hospital - Denver
- Presbyterian - St. Luke's Medical Center - Denver
- Rocky Mountain Cancer Centers - Denver Rose - Denver
- Veterans Affairs Medical Center - Denver - Denver
- CCOP - Colorado Cancer Research Program, Incorporated - Denver
- Swedish Medical Center - Englewood
California
- City of Hope Comprehensive Cancer Center - Duarte
- Rebecca and John Moores UCSD Cancer Center - La Jolla
- Cedars-Sinai Comprehensive Cancer Center at Cedars-Sinai Medical Center - Los Angeles
- Veterans Affairs Outpatient Clinic - Martinez - Martinez
- Naval Medical Center - San Diego - San Diego
- UCSF Comprehensive Cancer Center - San Francisco
Arizona
- CCOP - Mayo Clinic Scottsdale Oncology Program - Scottsdale
- Veterans Affairs Medical Center - Tucson - Tucson
Alabama
- Comprehensive Cancer Institute - Huntsville
Arkansas
- Veterans Affairs Medical Center - Little Rock - Little Rock
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-10-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00027859
The ClinicalTrials.gov registry entry for NCT00027859 describes a study currently listed as completed, categorized as Phase 3. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Eastern Cooperative Oncology Group, which has 141 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 4 interventions - of which docetaxel is the first listed.
NCT00027859 reports 20 study locations spanning 5 distinct geographic areas - top geographies include Colorado, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT00027859 about?
NCT00027859 is a clinical study titled "Hormone Therapy Compared With Combination Chemotherapy in Treating Patients With Prostate Cancer". RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Drugs such as ketoconazole may stop the production of androgens. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether hormone therapy is more ef...
What is the current status of trial NCT00027859?
This trial is currently completed. It is a Phase 3 study. The study started on 2003-10-08.
What conditions does trial NCT00027859 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT00027859?
The interventions under investigation include: docetaxel (DRUG), ketoconazole (DRUG), therapeutic hydrocortisone (DRUG), estramustine phosphate sodium (DRUG).
Who is sponsoring clinical trial NCT00027859?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00027859 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
RECRUITING · Phase 3
-
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
RECRUITING · Phase 3
-
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
RECRUITING · Phase 3
-
Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES)
RECRUITING · Phase 3
-
SAFE Nerve Sparing Guided by Micro-ultrasound (MUS)
RECRUITING · Phase 3
-
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
RECRUITING · Phase 3
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.